Skip to content

OPIANT PHARMACEUTICALS, INC.: 10-Q filed 2016-03-15

What OPIANT PHARMACEUTICALS, INC. reported in its quarterly report filed 2016-03-15 (fiscal Q2 2016): 26 published measures, 81 facts as tagged in accession 0001144204-16-088190.

This filing

Form
10-Q (quarterly report)
Filed
2016-03-15
Fiscal period
fiscal Q2 2016
Accession
0001144204-16-088190 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OPIANT PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-01-311,328,388USD
At 2015-07-31487,795USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-01-316,232,216USD
At 2015-07-318,874,520USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-01-31-4,903,828USD
At 2015-07-31-8,386,725USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-01-311,281,556USD
At 2015-07-31434,217USD
At 2015-01-311,060,919USD
At 2014-07-31254,770USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-11-01 to 2016-01-313,970,040USD92
2015-08-01 to 2016-01-31-7,139,977USD184
2014-11-01 to 2015-01-31-2,775,614USD92
2014-08-01 to 2015-01-31-3,550,951USD184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-11-01 to 2016-01-316,860,000USD92
2015-08-01 to 2016-01-316,980,000USD184
2014-11-01 to 2015-01-31560,000USD92
2014-08-01 to 2015-01-31560,000USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-01-31-60,511,063USD
At 2015-07-31-53,371,086USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2015-11-01 to 2016-01-311,880,279shares92
2015-08-01 to 2016-01-311,865,230shares184
2014-11-01 to 2015-01-311,806,303shares92
2014-08-01 to 2015-01-311,797,032shares184

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2015-11-01 to 2016-01-312,605,270shares92
2015-08-01 to 2016-01-311,865,230shares184
2014-11-01 to 2015-01-311,806,303shares92
2014-08-01 to 2015-01-311,797,032shares184

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2015-11-01 to 2016-01-312.11USD/shares92
2015-08-01 to 2016-01-31-3.83USD/shares184
2014-11-01 to 2015-01-31-1.54USD/shares92
2014-08-01 to 2015-01-31-1.98USD/shares184

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2015-11-01 to 2016-01-311.52USD/shares92
2015-08-01 to 2016-01-31-3.83USD/shares184
2014-11-01 to 2015-01-31-1.54USD/shares92
2014-08-01 to 2015-01-31-1.98USD/shares184

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2015-11-01 to 2016-01-310USD92
2015-08-01 to 2016-01-310USD184
2014-11-01 to 2015-01-310USD92
2014-08-01 to 2015-01-310USD184

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-08-01 to 2016-01-3185,434USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-11-01 to 2016-01-314,001,363USD92
2015-08-01 to 2016-01-31-7,099,467USD184
2014-11-01 to 2015-01-31-2,770,356USD92
2014-08-01 to 2015-01-31-3,530,470USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-01-311,308,639USD
At 2015-07-31467,360USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-11-01 to 2016-01-315,491USD92
2015-08-01 to 2016-01-3111,319USD184
2014-11-01 to 2015-01-3119,370USD92
2014-08-01 to 2015-01-3127,582USD184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-01-313,898,716USD
At 2015-07-313,574,520USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-11-01 to 2016-01-312,858,637USD92
2015-08-01 to 2016-01-3114,079,467USD184
2014-11-01 to 2015-01-313,330,356USD92
2014-08-01 to 2015-01-314,090,470USD184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-11-01 to 2016-01-31373,059USD92
2015-08-01 to 2016-01-31802,509USD184
2014-11-01 to 2015-01-311,191,747USD92
2014-08-01 to 2015-01-311,243,848USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-01-311,886,890shares
At 2015-07-311,841,866shares

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2016-01-3119,749USD
At 2015-07-3120,435USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2015-11-01 to 2016-01-313,970,040USD92
2015-08-01 to 2016-01-31-7,139,977USD184
2014-11-01 to 2015-01-31-2,775,614USD92
2014-08-01 to 2015-01-31-3,550,951USD184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-11-01 to 2016-01-312,485,578USD92
2015-08-01 to 2016-01-3113,276,958USD184
2014-11-01 to 2015-01-312,138,609USD92
2014-08-01 to 2015-01-312,846,622USD184

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2015-08-01 to 2016-01-31686USD184
2014-08-01 to 2015-01-31687USD184

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2015-11-01 to 2016-01-31-31,323USD92
2015-08-01 to 2016-01-31-40,510USD184
2014-11-01 to 2015-01-31-5,258USD92
2014-08-01 to 2015-01-31-20,481USD184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2015-08-01 to 2016-01-31-280,245USD184
2014-08-01 to 2015-01-31-122,986USD184

Inspect the source

Entity
OPIANT PHARMACEUTICALS, INC. / CIK 0001385508
Captured
SEC response SHA-256
2364e629461ca2a795db263ee8044ac545282f6ca3e3ea28eb9ce90156d0a955

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385508.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))